CD8 T cells use IFN-γ to protect against the lethal effects of a respiratory poxvirus infection

Journal of Immunology

Volumn 192, Issue 11, 2014, Pages 5415-5425

  Goulding, John ^a   Abboud, Georges ^a   Tahiliani, Vikas ^a   Desai, Pritesh ^a   Hutchinson, Tarun E ^a   Salek Ardakani, Shahram ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MESSENGER RNA; PERFORIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RESPONSE; DEATH; FEMALE; IN VIVO STUDY; INFECTION RESISTANCE; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; VACCINIA; VIRAL CLEARANCE; VIRAL RESPIRATORY TRACT INFECTION; VIRUS IMMUNITY; WEIGHT REDUCTION;

ANIMALS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; INTERFERON-GAMMA; LUNG; MICE; MICE, KNOCKOUT; RESPIRATORY TRACT DISEASES; VACCINIA; VACCINIA VIRUS;

EID: 84901280090     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400256     Document Type: Article

References (72)

1. Moss, B. 2007. Poxviridae: the viruses and their replication. In Fields Virology, 5th Ed., D. M. Knipe, ed. Philadelphia, Lippincott Williams & Wilkins, p. 2905-2946.
2. Cann, J. A., P. B. Jahrling, L. E. Hensley, and V. Wahl-Jensen. 2013. Comparative pathology of smallpox and monkeypox in man and macaques. J. Comp. Pathol. 148: 6-21.
3. Arita, I., Z. Jezek, L. Khodakevich, and K. Ruti. 1985. Human monkeypox: a newly emerged orthopoxvirus zoonosis in the tropical rain forests of Africa. Am. J. Trop. Med. Hyg. 34: 781-789.
4. Di Giulio, D. B., and P. B. Eckburg. 2004. Human monkeypox: an emerging zoonosis. Lancet Infect. Dis. 4: 15-25.
5. Baxby, D., M. Bennett, and B. Getty. 1994. Human cowpox 1969-93: a review based on 54 cases. Br. J. Dermatol. 131: 598-607.
6. Megid, J., I. A. Borges, J. S. Abrahão, G. S. Trindade, C. M. Appolinário, M. G. Ribeiro, S. D. Allendorf, J. M. Antunes, A. T. Silva-Fernandes, and E. G. Kroon. 2012. Vaccinia virus zoonotic infection, São Paulo State, Brazil. Emerg. Infect. Dis. 18: 189-191.
7. Nelson, J. B. 1938. The behavior of pox viruses in the respiratory tract: I. The response of mice to the nasal instillation of vaccinia virus. J. Exp. Med. 68: 401-412.
8. Turner, G. S. 1967. Respiratory infection of mice with vaccinia virus. J. Gen. Virol. 1: 399-402.
9. Williamson, J. D., R. W. Reith, L. J. Jeffrey, J. R. Arrand, and M. Mackett. 1990. Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J. Gen. Virol. 71: 2761-2767.
10. Reading, P. C., and G. L. Smith. 2003. A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection. J. Gen. Virol. 84: 1973-1983.
11. Schriewer, J., R. M. Buller, and G. Owens. 2004. Mouse models for studying orthopoxvirus respiratory infections. Methods Mol. Biol. 269: 289-308.
12. Goulding, J., R. Bogue, V. Tahiliani, M. Croft, and S. Salek-Ardakani. 2012. CD8 T cells are essential for recovery from a respiratory vaccinia virus infection. J. Immunol. 189: 2432-2440.
13. Roberts, J. A. 1962. Histopathogenesis of mousepox. I. Respiratory infection. Br. J. Exp. Pathol. 43: 451-461.
14. Chapman, J. L., D. K. Nichols, M. J. Martinez, and J. W. Raymond. 2010. Animal models of orthopoxvirus infection. Vet. Pathol. 47: 852-870.
15. Rivera, R., M. Hutchens, K. E. Luker, J. Sonstein, J. L. Curtis, and G. D. Luker. 2007. Murine alveolar macrophages limit replication of vaccinia virus. Virology 363: 48-58.
16. Bonduelle, O., D. Duffy, B. Verrier, C. Combadière, and B. Combadière. 2012. Cutting edge: Protective effect of CX3CR1+ dendritic cells in a vaccinia virus pulmonary infection model. J. Immunol. 188: 952-956.
17. Smith, G. L., C. T. Benfield, C. Maluquer de Motes, M. Mazzon, S. W. Ember, B. J. Ferguson, and R. P. Sumner. 2013. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J. Gen. Virol. 94: 2367-2392.
18. Chang, H. W., J. C. Watson, and B. L. Jacobs. 1992. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNAdependent protein kinase. Proc. Natl. Acad. Sci. USA 89: 4825-4829.
19. Rice, A. D., P. C. Turner, J. E. Embury, L. L. Moldawer, H. V. Baker, and R. W. Moyer. 2011. Roles of vaccinia virus genes E3L and K3L and host genes PKR and RNase L during intratracheal infection of C57BL/6 mice. J. Virol. 85: 550-567.
20. Beattie, E., J. Tartaglia, and E. Paoletti. 1991. Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology 183: 419-422.
21. Carroll, K., O. Elroy-Stein, B. Moss, and R. Jagus. 1993. Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase. J. Biol. Chem. 268: 12837-12842.
22. Mossman, K., C. Upton, R. M. Buller, and G. McFadden. 1995. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208: 762-769.
23. Alcamí, A., and G. L. Smith. 1995. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 69: 4633-4639.
24. Brandt, T. A., and B. L. Jacobs. 2001. Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J. Virol. 75: 850-856.
25. Sroller, V., V. Ludvíková, L. Maresová, P. Hainz, and S. Nemecková. 2001. Effect of IFN-gamma receptor gene deletion on vaccinia virus virulence. Arch. Virol. 146: 239-249.
26. Verardi, P. H., L. A. Jones, F. H. Aziz, S. Ahmad, and T. D. Yilma. 2001. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity. J. Virol. 75: 11-18.
27. Symons, J. A., D. C. Tscharke, N. Price, and G. L. Smith. 2002. A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence. J. Gen. Virol. 83: 1953-1964.
28. Salek-Ardakani, S., M. Moutaftsi, S. Crotty, A. Sette, and M. Croft. 2008. OX40 drives protective vaccinia virus-specific CD8 T cells. J. Immunol. 181: 7969-7976.
29. Salek-Ardakani, S., R. Flynn, R. Arens, H. Yagita, G. L. Smith, J. Borst, S. P. Schoenberger, and M. Croft. 2011. The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice. J. Clin. Invest. 121: 296-307.
30. Salek-Ardakani, S., J. Song, B. S. Halteman, A. G. Jember, H. Akiba, H. Yagita, and M. Croft. 2003. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J. Exp. Med. 198: 315-324.
31. Salek-Ardakani, S., R. Arens, R. Flynn, A. Sette, S. P. Schoenberger, and M. Croft. 2009. Preferential use of B7.2 and not B7.1 in priming of vaccinia virus-specific CD8 T cells. J. Immunol. 182: 2909-2918.
32. Tscharke, D. C., G. Karupiah, J. Zhou, T. Palmore, K. R. Irvine, S. M. Haeryfar, S. Williams, J. Sidney, A. Sette, J. R. Bennink, and J. W. Yewdell. 2005. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201: 95-104.
33. Moutaftsi, M., B. Peters, V. Pasquetto, D. C. Tscharke, J. Sidney, H. H. Bui, H. Grey, and A. Sette. 2006. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat. Biotechnol. 24: 817-819.
34. Zhao, Y., C. De Trez, R. Flynn, C. F. Ware, M. Croft, and S. Salek-Ardakani. 2009. The adaptor molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus. J. Immunol. 182: 6278-6286.
35. Harty, J. T., and V. P. Badovinac. 2002. Influence of effector molecules on the CD8(+) T cell response to infection. Curr. Opin. Immunol. 14: 360-365.
36. Mullbacher, A. 2003. Cell-mediated cytotoxicity in recovery from poxvirus infections. Rev. Med. Virol. 13: 223-232.
37. Topham, D. J., R. A. Tripp, and P. C. Doherty. 1997. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J. Immunol. 159: 5197-5200.
38. Ishikawa, E., M. Nakazawa, M. Yoshinari, and M. Minami. 2005. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice. J. Virol. 79: 7658-7663.
39. Brincks, E. L., A. Katewa, T. A. Kucaba, T. S. Griffith, and K. L. Legge. 2008. CD8 T cells utilize TRAIL to control influenza virus infection. J. Immunol. 181: 4918-4925.
40. Kägi, D., P. Seiler, J. Pavlovic, B. Ledermann, K. Burki, R. M. Zinkernagel, and H. Hengartner. 1995. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur. J. Immunol. 25: 3256-3262.
41. Seedhom, M. O., K. S. Mathurin, S. K. Kim, and R. M. Welsh. 2012. Increased protection from vaccinia virus infection in mice genetically prone to lymphoproliferative disorders. J. Virol. 86: 6010-6022.
42. Mullbacher, A., K. Ebnet, R. V. Blanden, R. T. Hla, T. Stehle, C. Museteanu, and M. M. Simon. 1996. Granzyme A is critical for recovery of mice from infection with the natural cytopathic viral pathogen, ectromelia. Proc. Natl. Acad. Sci. USA 93: 5783-5787.
43. Mullbacher, A., R. T. Hla, C. Museteanu, and M. M. Simon. 1999. Perforin is essential for control of ectromelia virus but not related poxviruses in mice. J. Virol. 73: 1665-1667.
44. Mullbacher, A., P. Waring, R. Tha Hla, T. Tran, S. Chin, T. Stehle, C. Museteanu, and M. M. Simon. 1999. Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc. Natl. Acad. Sci. USA 96: 13950-13955.
45. Xu, R., A. J. Johnson, D. Liggitt, and M. J. Bevan. 2004. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol. 172: 6265-6271.
46. Andrews, D. M., C. E. Andoniou, P. Fleming, M. J. Smyth, and M. A. Degli-Esposti. 2008. The early kinetics of cytomegalovirus-specific CD8+ T-cell responses are not affected by antigen load or the absence of perforin or gamma interferon. J. Virol. 82: 4931-4937.
47. Mo, X. Y., R. A. Tripp, M. Y. Sangster, and P. C. Doherty. 1997. The cytotoxic T-lymphocyte response to Sendai virus is unimpaired in the absence of gamma interferon. J. Virol. 71: 1906-1910.
48. Nguyen, H. H., F. W. van Ginkel, H. L. Vu, M. J. Novak, J. R. McGhee, and J. Mestecky. 2000. Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice. J. Virol. 74: 5495-5501.
49. Huang, S., W. Hendriks, A. Althage, S. Hemmi, H. Bluethmann, R. Kamijo, J. Vilcek, R. M. Zinkernagel, and M. Aguet. 1993. Immune response in mice that lack the interferon-gamma receptor. Science 259: 1742-1745.
50. Remakus, S., and L. J. Sigal. 2011. Gamma interferon and perforin control the strength, but not the hierarchy, of immunodominance of an antiviral CD8+ T cell response. J. Virol. 85: 12578-12584.
51. Wasilenko, S. T., A. F. Meyers, K. Vander Helm, and M. Barry. 2001. Vaccinia virus infection disarms the mitochondrion-mediated pathway of the apoptotic cascade by modulating the permeability transition pore. J. Virol. 75: 11437-11448.
52. Wasilenko, S. T., T. L. Stewart, A. F. Meyers, and M. Barry. 2003. Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis. Proc. Natl. Acad. Sci. USA 100: 14345-14350.
53. Kettle, S., A. Alcamí, A. Khanna, R. Ehret, C. Jassoy, and G. L. Smith. 1997. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta- converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J. Gen. Virol. 78: 677-685.
54. Kawakami, Y., Y. Tomimori, K. Yumoto, S. Hasegawa, T. Ando, Y. Tagaya, S. Crotty, and T. Kawakami. 2009. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J. Exp. Med. 206: 1219-1225.
55. Martinez, J., X. Huang, and Y. Yang. 2010. Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PLoS Pathog. 6: e1000811.
56. Bukowski, J. F., B. A. Woda, S. Habu, K. Okumura, and R. M. Welsh. 1983. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J. Immunol. 131: 1531-1538.
57. Smith, P. M., R. M. Wolcott, R. Chervenak, and S. R. Jennings. 1994. Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-gamma (IFN-gamma). Virology 202: 76-88.
58. Lucin, P., I. Pavić, B. Polić, S. Jonjić, and U. H. Koszinowski. 1992. Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J. Virol. 66: 1977-1984.
59. Leist, T. P., M. Eppler, and R. M. Zinkernagel. 1989. Enhanced virus replication and inhibition of lymphocytic choriomeningitis virus disease in anti-gamma interferon-treated mice. J. Virol. 63: 2813-2819.
60. Tishon, A., H. Lewicki, G. Rall, M. Von Herrath, and M. B. Oldstone. 1995. An essential role for type 1 interferon-gamma in terminating persistent viral infection. Virology 212: 244-250.
61. Karupiah, G., Q.W. Xie, R. M. Buller, C. Nathan, C. Duarte, and J. D. MacMicking. 1993. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 261: 1445-1448.
62. Karupiah, G., T. N. Fredrickson, K. L. Holmes, L. H. Khairallah, and R. M. Buller. 1993. Importance of interferons in recovery from mousepox. J. Virol. 67: 4214-4226.
63. Karupiah, G., R. M. Buller, N. Van Rooijen, C. J. Duarte, and J. Chen. 1996. Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection. J. Virol. 70: 8301-8309.
64. Kohonen-Corish, M. R., N. J. King, C. E. Woodhams, and I. A. Ramshaw. 1990. Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur. J. Immunol. 20: 157-161.
65. Ramshaw, I., J. Ruby, A. Ramsay, G. Ada, and G. Karupiah. 1992. Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo. Immunol. Rev. 127: 157-182.
66. Ruby, J., and I. Ramshaw. 1991. The antiviral activity of immune CD8+ T cells is dependent on interferon-gamma. Lymphokine Cytokine Res. 10: 353-358.
67. Harris, N., R. M. Buller, and G. Karupiah. 1995. Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J. Virol. 69: 910-915.
68. Melková, Z., and M. Esteban. 1995. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. J. Immunol. 155: 5711-5718.
69. Lukacher, A. E., V. L. Braciale, and T. J. Braciale. 1984. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J. Exp. Med. 160: 814-826.
70. Eichelberger, M., W. Allan, M. Zijlstra, R. Jaenisch, and P. C. Doherty. 1991. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J. Exp. Med. 174: 875-880.
71. Topham, D. J., R. A. Tripp, S. R. Sarawar, M. Y. Sangster, and P. C. Doherty. 1996. Immune CD4+ T cells promote the clearance of influenza virus from major histocompatibility complex class II -/- respiratory epithelium. J. Virol. 70: 1288-1291.
72. Hamada, H., E. Bassity, A. Flies, T. M. Strutt, Mde. L. Garcia-Hernandez, K. K. McKinstry, T. Zou, S. L. Swain, and R. W. Dutton. 2013. Multiple redundant effector mechanisms of CD8+ T cells protect against influenza infection. J. Immunol. 190: 296-306.